Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs from Eli Lilly (NYSE: LLY) and its peers reshape both waistlines and Wall Street models, a small device maker, Modular Medical (NASDAQ: MODD), just secured a regulatory green light that could make insulin delivery look a lot more like tapping to pay than priming a pump.
Walmart Puts GLP‑1s in the Center Aisle
Walmart (NYSE: WMT) is expanding its Better Care Services digital health platform to plug directly into America’s GLP‑1 obsession, adding weight‑management services for customers using or exploring GLP‑1 therapies. The platform connects customers with third‑party telehealth providers such as Aaptiv and Curai Health, who can handle medical evaluation and prescribing, while Walmart’s nearly 4,600 pharmacies stand ready to fill GLP‑1 prescriptions and deliver related products.
In parallel, Walmart has redesigned its “GLP‑1 digital destination” on Walmart.com to showcase GLP‑1 medications alongside medically reviewed nutrition guidance, vitamins, and other wellness products, essentially turning a blockbuster drug class into a full‑stack retail ecosystem. Launched earlier this year, Better Care Services is pitched as a one‑stop, virtual front door for urgent care, behavioral health, nutrition, and now weight‑loss support, giving Walmart a health‑tech narrative that pairs neatly with its growing digital sales and e‑commerce ambitions.
The GLP‑1 Gold Rush: Lilly, Novo, and the Usual (Obesity) Suspects
Behind Walmart’s strategy is a simple equation: GLP‑1 drugs have gone from endocrinology niche to cultural phenomenon, dragging a handful of pharmaceutical tickers into market‑darling territory. Eli Lilly’s (NYSE: LLY) injectable GLP‑1 franchise, led by Mounjaro for diabetes and Zepbound for obesity, has become the world’s best‑selling drug product, with sales that topped tens of billions of dollars last year as it gained share from Novo Nordisk’s (NYSE: NVO) Ozempic and Wegovy. Novo Nordisk (NYSE: NVO), for its part, has grown GLP‑1 revenue across diabetes and obesity indications from the tens of billions toward what analysts see as a path to roughly three‑fold expansion over the next decade, underscoring how durable investors expect this category to be.
The race is no longer just a two‑horse sprint; Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) are pushing mid‑stage GLP‑1 and incretin‑based obesity programs that could begin to carve out share later this decade if clinical data cooperate. Even with bumps in the road—Pfizer’s early pipeline setbacks and the usual safety debates—analysts still see combined GLP‑1‑based sales at Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Pfizer (NYSE: PFE), and Amgen (NASDAQ: AMGN) surpassing 90 billion dollars by 2030, a revenue pile big enough to warrant its own risk factor in fast‑food filings.
Modular Medical’s Pivot: A Small-Cap Device With a Big-Cap Problem in Sight
While GLP‑1s grab headlines, insulin isn’t quietly retiring; it is quietly demanding better hardware, and that is where Modular Medical (NASDAQ: MODD) has stepped in. The company has received FDA 510(k) clearance for its Pivot tubeless insulin patch pump, a next‑generation device designed for people with diabetes who want something simpler than traditional pump rigs but more flexible than multiple daily injections. The Pivot system is a two‑part, tubeless patch pump with a removable 3 mL insulin reservoir, smartphone‑based control, and a disposable power source, features aimed at an “almost‑pumper” market estimated at around 3 billion dollars in annual opportunity.
Clearance opens the door to commercial sales in the United States, with Modular Medical (NASDAQ: MODD) signaling plans to ship initial units by the end of the second quarter of 2026, after building production capacity for thousands of early users. The company also has its sights on Europe, targeting a CE Mark as soon as late 2026 or early 2027, a timeline that, if met, would give this small‑cap a front‑row seat to the global debate over how technology can make long‑term diabetes management less intrusive and more consumer‑friendly.
When Retail Meets Pharma Meets Devices
Put together, Walmart (NYSE: WMT), the GLP‑1 heavyweights, and Modular Medical (NASDAQ: MODD) illustrate how the weight‑management boom is blurring the lines between retailer, manufacturer, and device innovator. Walmart’s Better Care Services funnels consumers into a curated network of telehealth partners and pharmacy services at the very moment Eli Lilly (NYSE: LLY) launches new formulations, such as its oral GLP‑1 pill Foundayo, which kicks off a fresh showdown with Novo Nordisk (NYSE: NVO) in both diabetes and obesity markets. As GLP‑1s reshape demand for obesity and diabetes care, they may indirectly expand the addressable market for connected devices like Modular Medical’s Pivot pump, especially for patients who still require insulin but expect smartphone‑level convenience.
For investors, this triangulation creates a layered trade: Walmart (NYSE: WMT) seeking higher‑margin, service‑driven healthcare revenue; pharma majors like Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Pfizer (NYSE: PFE), and Amgen (NASDAQ: AMGN) scaling a category that could exceed 90 billion dollars in annual GLP‑1‑based sales; and device specialists such as Modular Medical (NASDAQ: MODD) trying to turn regulatory milestones into commercial scale. The common thread is simple enough: in modern healthcare, the prescription is only the beginning—what happens across the retail shelf, the telehealth screen, and the insulin pump may ultimately decide who turns this GLP‑1 wave into enduring shareholder returns.
The Sources
- Walmart expands digital health platform’s weight loss offerings – Yahoo Finance
https://finance.yahoo.com/sectors/healthcare/articles/walmart-expands-digital-health-platform-124100063.htmlfinance.yahoo - Walmart expands access to weight management support services – Yahoo Finance
https://finance.yahoo.com/sectors/healthcare/articles/walmart-expands-access-weight-management-153900614.htmlfinance.yahoo - New Year, New You: Walmart launches Better Care Services and digital health offerings – Yahoo Finance
https://finance.yahoo.com/news/walmart-launches-better-care-services-180000913.htmlfinance.yahoo - Walmart Expands Better Care Services Health Platform – Progressive Grocer
https://progressivegrocer.com/walmart-expands-better-care-services-health-platformprogressivegrocer - Walmart Expands Health Management Services Platform – Intellectia.AI
https://intellectia.ai/news/stock/walmart-expands-health-management-services-platformintellectia - Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump – Yahoo Finance
https://finance.yahoo.com/sectors/healthcare/articles/modular-medical-receives-fda-510-130000624.htmlfinance.yahoo - Modular Medical wins FDA clearance for Pivot pump – Stock Titan
https://www.stocktitan.net/news/MODD/modular-medical-receives-fda-510-k-clearance-for-pivot-tubeless-h2yibgu7uc0k.htmlstocktitan - Modular Medical Achieves Key Manufacturing Milestone for Pivot Pump – GlobeNewswire via Yahoo/other listing
https://finance.yahoo.com/news/modular-medical-achieves-key-manufacturing-133000481.htmlfinance.yahoo - Walmart’s new Better Care digital health push could be a game changer – Yahoo Finance
https://finance.yahoo.com/news/walmart-better-care-digital-health-050950649.htmlfinance.yahoo - Walmart results show split consumer as digital sales grow – Yahoo Finance (context on Walmart’s digital business)
https://finance.yahoo.com/video/walmart-results-show-split-consumer-203203856.htmlfinance.yahoo - Walmart expands digital health platform’s weight loss offerings – Healthcare Dive
https://www.healthcaredive.com/news/walmarts-expands-digital-health-platform-glp1s/817681/healthcaredive - Lilly launches GLP‑1 pill, kicking off showdown with Novo Nordisk – BioPharma Dive
https://www.biopharmadive.com/news/lilly-foundayo-obesity-pill-launch-price-wegovy/817052/biopharmadive - Obesity Drug Stocks: Where to Invest Now – Morningstar
https://www.morningstar.com/stocks/obesity-drug-stocks-where-invest-now-2morningstar - Obesity Drug Stocks: Time to Buy? – Morningstar
https://www.morningstar.com/stocks/obesity-drug-stocks-time-buymorningstar
